Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
News|Podcasts|February 27, 2026
The Ron Lanton Report: Is Healthcare Consolidation Reaching Its Limits?
Author(s)Ron Lanton, Nicholas Jacobus
The episode will explore structural implications for supply chains, distribution models, and international strategy—not a political discussion, but a forward-looking planning lens.
Advertisement
This episode of The Ron Lanton Report examines whether healthcare consolidation in the United States may be approaching a structural limit. For years, industry strategy has assumed continued consolidation across health systems, purchasing organizations, and distribution channels, driving efficiency through scale, centralized purchasing, and simplified contracting.
The discussion explores how even modest fragmentation could reshape supply chains, contracting dynamics, and distribution predictability. If consolidation slows, manufacturers and distributors may face more complex contracting environments, more distributed negotiating leverage, and less centralized purchasing behavior.
The episode also considers the international implications, including how changes in the U.S. healthcare structure could influence global launch strategies, pricing assumptions, and cross-border reference pricing systems.
Advertisement
Related to this article
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
Real-world data show weight loss after switching to the Wegovy pill, Lilly reports positive hand and foot atopic dermatitis data, and Teva wins FDA approval for a Xgeva biosimilar.
Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.
Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
FDA expands Winrevair’s label with HYPERION data, formalizes the use of non-animal testing methods, and Amgen reports positive Phase 3 results for dazodalibep in Sjögren disease.
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Advertisement
Advertisement